Embrace Technology Innovations to Optimize LNP Formulation, Alternative LNP Raw Materials, Process Control to Achieve Seamless Scale-Up, Compliance & Cost Effectiveness
The global nanopharmaceutical drugs market, catalyzed by the success of Pfizer/BioNTech and Moderna’s mRNA vaccines, is poised to reach US$82.7 billion by 2027. The demand of novel LNP to support the delivery of oligonucleotide and nucleic acid-based therapies is growing at an exponential rate. With the overwhelming possibilities of lipid nanoparticles, there are key questions on formulation, process development and scalability that still need to be answered. There has been no better time to join forces and help accelerate the development of truly remedial LNP therapeutics.
To know more visit: https://ter.li/8hrml3